Two China-Origin Immunology Assets Land the Same Morning: Hansoh's Oral IL-23 Anchors a $2.3B Nasdaq Debut and Innovent's CD40L Antibody Rebuilds Spero, as Lilly Pays $2.8B for AtaiBeckley

Two China-origin immunology assets crossed the Pacific within hours of each other on July 14, and both were structured as company-defining transactions rather than portfolio additions. Avere Therapeutics licensed AVR-001, a once-weekly oral IL-23 antagonist, from Hansoh Pharmaceutical for $120M upfront and up to $2.18B in milestones plus mid-single to low-double-digit royalties - then used it to go public, merging into Nasdaq-listed NextCure in an all-stock reverse merger that leaves pre-merger Avere holders with roughly 98% of the combined company (ticker AVRX, close expected in 2H 2026) and pairing it with a $320M private placement led by Fairmount and Hansoh. Avere's leadership - CEO Andrew Cheng, CDO Kitty Yale and CFO William White - previously took Akero Therapeutics from pre-IPO through Novo Nordisk's acquisition. A Hansoh Phase 1b in China suggested AVR-001 could hold its own against a daily first-generation oral inhibitor on psoriasis; Avere plans a Phase 2b psoriasis study next year with a readout penciled in for 1H 2028, plus a Phase 2b in ulcerative colitis.

The same morning, Spero Therapeutics licensed SP001 (formerly IBI355) from Innovent Biologics - a third-generation Fc-silent anti-CD40L antibody engineered to avoid the platelet-activation liability that sank earlier drugs against this target. Spero takes global rights, Innovent retains Greater China, and the package runs to up to $1.1B in development, regulatory and commercial milestones plus tiered royalties, with the upfront undisclosed. The deal converts Spero from an antibiotics company into an immunology company: it plans a Phase 2 in IgG4-related disease in Q2 2027 and funded the pivot by selling Healthcare Royalty a slice of its Utebzi royalty stream for $105M. On M&A, Lilly continued its takeover run with a $2.8B upfront agreement for AtaiBeckley and its intranasal 5-MeO-DMT candidate BPL-003, while Samsung Biologics bid CHF 1.46B for peptide CDMO PolyPeptide. For BD readers the pattern to note is that neither China-out license this week was a big-pharma bolt-on - both were the entire strategic rationale for the acquiring vehicle.

July 14, 2026 - FDA Approves Celcuity’s REVTORPYK (gedatolisib) in HR+/HER2-, PIK3CA Wild-Type Advanced Breast Cancer

The FDA approved REVTORPYK (gedatolisib; Celcuity) for adults with hormone-receptor-positive, HER2-negative, locally advanced or metastatic breast cancer without a detected PIK3CA mutation, following progression on or after at least one line of endocrine therapy. Gedatolisib is a pan-PI3K and mTORC1/2 inhibitor targeting the PAM pathway. In the Phase 3 VIKTORIA-1 trial, gedatolisib plus palbociclib and fulvestrant reduced the risk of progression or death by 76%, and gedatolisib plus fulvestrant by 67%, versus fulvestrant alone in PIK3CA wild-type patients. Celcuity has said it plans to submit a supplemental NDA in Q3 2026 covering the PIK3CA-mutated population.

BD Implication: The approval carves out the PIK3CA wild-type segment that existing PI3K-alpha inhibitors do not serve, establishing that biomarker-negative positioning can be a differentiator rather than a fallback. For China-origin PAM-pathway and CDK4/6-combination assets seeking Western partners, the practical lesson is that a clearly defined, underserved biomarker segment with a large hazard-ratio effect is a cleaner route to approval than head-to-head competition in the mutated population.

July 16, 2026 - InnoCare’s TYK2 Inhibitor Soficitinib Hits Its Primary Endpoint in a Phase 2 Vitiligo Study Run in China

InnoCare Pharma reported that the Phase 2 portion of its Phase 2/3 study of soficitinib (ICP-332), a TYK2 JH1-domain inhibitor, met its primary endpoint in nonsegmental vitiligo, clearing the program to advance into the Phase 3 portion. In the China-based study, 24 weeks of daily oral dosing produced a 41.2% change in the Facial Vitiligo Area Scoring Index (F-VASI) on the high dose and 38.8% on the low dose, versus 2.2% on placebo; both doses separated significantly from placebo. InnoCare described the safety profile as favorable and consistent with prior studies with no new safety signals, and has not yet released detailed efficacy or safety data, which it plans to present at a scientific congress or publish. Soficitinib is also in mid- to late-phase trials in atopic dermatitis, chronic spontaneous urticaria, plaque psoriasis and prurigo nodularis; a second TYK2 candidate, ICP-488, is in Phase 2 cutaneous lupus and Phase 3 plaque psoriasis.

BD Implication: A China-run registrational-intent study delivering a clean placebo separation in an indication where Incyte's Opzelura is the only approved option, and where Takeda and BMS are running their own trials, is exactly the profile Western buyers screen for. Note the mechanistic differentiation worth diligencing: soficitinib binds the TYK2 JH1 (catalytic) domain, whereas Sotyktu, zasocitinib and InnoCare's own ICP-488 bind JH2 - a distinction that cuts both ways on selectivity and should be a first-order question in any partnering conversation.

July 16, 2026 - Takeda’s Zasocitinib Posts Difficult-to-Treat-Site Phase 3 Psoriasis Data

Takeda presented secondary-endpoint data at the American Academy of Dermatology Innovation Academy from two Phase 3 trials of the once-daily oral TYK2 inhibitor zasocitinib enrolling a combined 1,801 patients with moderate-to-severe plaque psoriasis. For scalp psoriasis, 77% and 74% of patients across the two trials achieved clear or almost-clear skin at Week 16, versus 7% and 13% on placebo and 42% and 30% on Amgen's Otezla. For palms and soles, the figure was near 70%, versus 22% and 10% on placebo and 44% and 43% on Otezla. Takeda had previously reported that more than 50% of patients achieved PASI 90 and about 30% achieved clear skin. Takeda acquired zasocitinib from Nimbus Therapeutics for $4B upfront in 2022, forecasts peak revenue of $3B to $6B across psoriasis and psoriatic arthritis, and plans to file with the FDA before the end of its current financial year.

BD Implication: Difficult-site efficacy - scalp, palms, soles, nails - is emerging as the differentiator in a psoriasis market where overall PASI response is table stakes, and it sets the evidentiary bar that China-origin oral entrants such as Hansoh's AVR-001 (licensed to Avere this week) and InnoCare's ICP-488 will be measured against. Sponsors positioning oral psoriasis assets for out-licensing should be generating high-impact-site and active-comparator data early, not deferring it to post-approval label expansion.

Validation notes: Terms for the Spero/Innovent upfront payment and for the Halozyme/Incyte agreement were not disclosed by the parties and are reported as undisclosed rather than estimated. Reported US-dollar equivalents for the Samsung Biologics offer for PolyPeptide varied across outlets (approximately $1.8B to $1.9B); the CHF 1.46B implied equity value from the offer announcement is used here. InnoCare's Phase 2 vitiligo figures are company-reported topline values pending full presentation. The Avere/Hansoh and Spero/Innovent transactions are dated by announcement (July 14, 2026), not by close.